Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 171

1.

Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.

Angulo P, Kaushik G, Subramaniam D, Dandawate P, Neville K, Chastain K, Anant S.

J Hematol Oncol. 2017 Jan 7;10(1):10. doi: 10.1186/s13045-016-0373-z. Review.

2.

Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.

Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, Esfandiari N, Ma M, Baracos VE.

J Cachexia Sarcopenia Muscle. 2016 May;7(2):126-35. doi: 10.1002/jcsm.12039. Epub 2015 Jun 9.

3.

Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests.

Guéchot J, Boursier J, de Ledinghen V, Poynard T, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group and/or AFEF.

Clin Chem Lab Med. 2015 Jul;53(8):1135-7. doi: 10.1515/cclm-2015-0241. No abstract available.

4.

Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications.

Angulo P, Machado MV, Diehl AM.

Semin Liver Dis. 2015 May;35(2):132-45. doi: 10.1055/s-0035-1550065. Epub 2015 May 14. Review.

PMID:
25974899
5.

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F.

Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.

6.

Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.

Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P.

Dig Liver Dis. 2015 Mar;47(3):181-90. doi: 10.1016/j.dld.2014.09.020. Epub 2014 Nov 18. Review.

7.

The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE, Alkhouri N.

Dig Dis Sci. 2015 May;60(5):1440-7. doi: 10.1007/s10620-014-3494-7. Epub 2014 Dec 25.

PMID:
25540086
8.

An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.

Boursier J, de Ledinghen V, Poynard T, Guéchot J, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group; AFEF.

J Hepatol. 2015 Apr;62(4):807-15. doi: 10.1016/j.jhep.2014.10.042. Epub 2014 Nov 5.

PMID:
25450206
9.

Noninvasive prediction of hepatic steatosis.

Cumberledge J, Angulo P.

Am J Gastroenterol. 2014 Sep;109(9):1415-6. doi: 10.1038/ajg.2014.265.

PMID:
25196872
10.

Hepatic steatosis and steatohepatitis: Are they really two distinct entities?

Fielding CM, Angulo P.

Curr Hepatol Rep. 2014 Jun 1;13(2):151-158.

11.

Right upper-quadrant pain in a patient with drug abuse, secondary syphilis and occult hepatitis B virus.

Fielding CM, Angulo P.

Med Princ Pract. 2014;23(5):471-4. doi: 10.1159/000360401. Epub 2014 Mar 18.

12.

INTERVENCIONES.

Prado S, López-Ibor, Angulo P, Martínez-Fornés, Fernández B, Aragón V, Campos.

An R Acad Nac Med (Madr). 2014;131(2):492-6. Spanish. No abstract available.

PMID:
27400569
13.

INTERVENCIONES.

Vela M, Angulo P, de Peralta T, Manuel C, Rodríguez R.

An R Acad Nac Med (Madr). 2014;131(2):469-76. Spanish. No abstract available.

PMID:
27400567
14.

Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease.

Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, Liaquat H, Mezzabotta L, Lee E, Bugianesi E.

Clin Gastroenterol Hepatol. 2014 Jul;12(7):1163-1169.e1. doi: 10.1016/j.cgh.2013.11.035. Epub 2013 Dec 14.

15.

Noninvasive evaluation of NAFLD.

Castera L, Vilgrain V, Angulo P.

Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):666-75. doi: 10.1038/nrgastro.2013.175. Epub 2013 Sep 24. Review.

PMID:
24061203
16.

Strengthening the bones in primary biliary cirrhosis.

Angulo P.

Hepatology. 2013 Dec;58(6):1871-3. doi: 10.1002/hep.26696. Epub 2013 Oct 17. No abstract available.

17.

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J.

Gastroenterology. 2013 Oct;145(4):782-9.e4. doi: 10.1053/j.gastro.2013.06.057. Epub 2013 Jul 13.

18.

PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.

Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.

J Surg Res. 2013 Nov;185(1):225-30. doi: 10.1016/j.jss.2013.05.016. Epub 2013 May 25.

19.

Risk factors for venous thromboembolism in patients with chronic liver disease.

Walsh KA, Lewis DA, Clifford TM, Hundley JC, Gokun Y, Angulo P, Davis GA.

Ann Pharmacother. 2013 Mar;47(3):333-9. doi: 10.1345/aph.1R496. Epub 2013 Mar 12.

PMID:
23482730
20.

Can NASH be diagnosed, graded, and staged noninvasively?

Grandison GA, Angulo P.

Clin Liver Dis. 2012 Aug;16(3):567-85. doi: 10.1016/j.cld.2012.05.001. Epub 2012 Jun 26. Review.

Supplemental Content

Loading ...
Support Center